STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRAW
  4. [Form 4] Traws Pharma, Inc. Insider Trading Activity

Insider Filing: 23k Option Grant to Traws Pharma Board Member

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 disclosing that director Clarke Trafford was granted 23,000 stock options on 06/19/2025. The options carry a $1.65 exercise price, vest 100 % after one year (06/19/2026) and expire on 06/19/2035. Following the grant, the reporting person now beneficially owns 23,000 derivative securities directly. No shares of common stock were bought or sold, and there are no indications of 10b5-1 trading plans or additional transactions in this filing.

Positive

  • None.

Negative

  • None.
Insider Clarke Trafford
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to purchase) 23,000 $0.00 $0.00
Holdings After Transaction: Stock Option (right to purchase) — 23,000 shares (Direct)
Footnotes (1)
  1. F1. These options vest 100% on the first anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many stock options did director Clarke Trafford receive according to the Form 4 for TRAW?
The filing shows a grant of 23,000 stock options to Clarke Trafford.

What is the exercise price and vesting schedule of the new Traws Pharma options?
Each option has a $1.65 exercise price and vests 100 % on 06/19/2026, one year after the grant date.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clarke Trafford
(Last) (First) (Middle)
C/O TRAWS PHARMA, INC.
12 PENNS TRAIL
(Street)
NEWTOWN PA 18940
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to purchase) $1.65 06/19/2025 A 23,000 06/19/2026(1) 06/19/2035 Common Stock 23,000 $0 23,000 D
Explanation of Responses:
1. These options vest 100% on the first anniversary of the grant date.
/s/ Trafford Clarke 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR